| |
Relapse
|
NRM
|
Acute GVHD
|
Chronic GVHD
|
LFS
|
OS
|
|---|
| |
p value
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
OR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
|---|
|
RIC vs. MAC
|
|
All
|
0.07
|
1.31 (0.98–1.75)
|
0.76
|
0.95 (0.69–1.31)
|
0.32
|
0.82 (0.55–1.21)
|
0.21
|
0.80 (0.56–1.14)
|
0.27
|
1.13 (0.91–1.40)
|
0.44
|
1.09 (0.87–1.36)
|
|
AML
|
0.09
|
1.34 (0.95–1.87)
|
0.17
|
0.78 (0.54–1.12)
| | | | |
0.74
|
1.04 (0.81–1.34)
|
0.79
|
0.97 (0.75–1.25)
|
|
ALL
|
0.5
|
1.23 (0.67–2.26)
|
0.18
|
1.5 (0.83–2.72)
| | | | |
0.17
|
1.34 (0.88–2.05)
|
0.10
|
1.44 (0.94–2.22)
|
|
Age at SCT
|
|
1. <30 (ref)
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
|
|
2. (30–40) vs. 1
|
0.91
|
1.02 (0.68–1.54)
|
0.27
|
0.79 (0.51–1.20)
|
0.98
|
1.01 (0.60–1.70)
|
0.25
|
0.75 (0.46–1.22)
|
0.47
|
0.90 (0.67–1.20)
|
0.52
|
0.91 (0.67–1.23)
|
|
3. (40–50) vs. 2
|
0.43
|
0.84 (0.55–1.28)
|
0.74
|
1.08 (0.69–1.69)
|
0.98
|
1.01 (0.58–1.77)
|
0.70
|
0.91 (0.56–1.48)
|
0.74
|
0.95 (0.70–1.29)
|
0.79
|
0.96 (0.69–1.32)
|
|
4. ≥ 50 vs. 3
|
0.11
|
1.33 (0.93–1.90)
|
0.48
|
0.87 (0.59–1.28)
|
0.06
|
1.62 (0.98–2.70)
|
0.44
|
1.18 (0.77–1.79)
|
0.52
|
1.09 (0.84–1.42)
|
0.79
|
1.04 (0.79–1.36)
|
|
ALL vs. AML
|
0.04
|
1.39 (1.02–1.91)
|
0.37
|
1.16 (0.84–1.61)
|
0.65
|
1.10 (0.73–1.66)
|
0.50
|
1.13 (0.79–1.63)
|
0.03
|
1.28 (1.02–1.61)
|
0.03
|
1.30 (1.03–1.64)
|
|
Status at SCT
|
|
CR1 (ref)
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
|
|
≥ CR2 vs. CR1
|
0.05
|
1.46 (1.01–2.13)
|
0.45
|
1.15 (0.80–1.63)
|
0.35
|
1.24 (0.80–1.92)
|
0.23
|
1.25 (0.87–1.78)
|
0.05
|
1.30 (1.00–1.67)
|
0.01
|
1.40 (1.07–1.83)
|
|
Active dis. vs. CR1
|
<10–4
|
4.43 (3.20–6.12)
|
0.0002
|
1.86 (1.34–2.59)
|
0.85
|
1.04 (0.68–1.60)
|
0.45
|
1.17 (0.78–1.75)
|
<10–4
|
2.94 (2.34–3.70)
|
<10–4
|
2.92 (2.30–3.72)
|
|
PB vs. BM
|
0.85
|
1.03 (0.77–1.37)
|
0.59
|
1.09 (0.80–1.48)
|
0.0008
|
1.96 (1.32–2.92)
|
0.005
|
1.64 (1.16–2.30)
|
0.63
|
1.05 (0.85–1.30)
|
0.58
|
1.06 (0.85–1.32)
|
|
PT-Cy-based vs. other
|
0.94
|
0.99 (0.72–1.36)
|
0.02
|
0.63 (0.44–0.92)
|
0.11
|
0.69 (0.44–1.09)
|
0.46
|
1.15 (0.79–1.69)
|
0.10
|
0.82 (0.64–1.04)
|
0.16
|
0.83 (0.65–1.07)
|
|
Year of SCT
|
|
2001–2005 (ref)
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
|
|
2005–2007
|
0.86
|
1.08 (0.48–2.43)
|
0.74
|
0.89 (0.45–1.77)
|
0.62
|
1.24 (0.44–3.51)
|
0.17
|
2.03 (0.74–5.56)
|
0.89
|
0.96 (0.57–1.63)
|
0.84
|
1.06 (0.61–1.83)
|
|
2008–2012
|
0.98
|
0.99 (0.47–2.09)
|
0.22
|
0.68 (0.36–1.27)
|
0.27
|
1.68 (0.67–4.22)
|
0.14
|
2.04 (0.80–5.19)
|
0.40
|
0.81 (0.50–1.31)
|
0.60
|
0.87 (0.53–1.44)
|
-
Active dis active disease, BM bone marrow, PT-Cy-based post-transplant cyclophosphamide associated to one calcineurin inhibitor and mycophenolate mofetyl, CR complete remission, GVHD graft-versus-host-disease, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloablative conditioning, OS overall survival, PB peripheral blood, Ref reference, RIC reduced intensity conditioning, SCT allogeneic stem cell transplantation
